Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2017;391:31-40.
More than 500 000 percutaneous coronary intervention (PCI) procedures are performed worldwide each year for stable coronary artery disease (CAD). In addition to medical therapy, physiologically targeted PCI reduces urgent revascularisation in this group1; however, unlike in acute coronary syndromes, evidence supporting a reduction in myocardial infarction and mortality is lacking,2 especially in those with low ischaemic burden.3 Consequently, in stable CAD, PCI is used predominantly for symptomatic relief. It is therefore remarkable that, 40 years after Andreas Grüntzig’s first PCI, we only now have results of the first double-blind, placebo-controlled trial of PCI in stable angina: the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) trial.4
Patients with stable angina and single-vessel …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.